Accessibility Log In Help Join The Motley Fool

Evelo Biosciences (NASDAQ: EVLO)

$0.05

(13.6%)

$0.01

Price as of April 18, 2024, 10:32 a.m. ET

Evelo Biosciences Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
EVLO	-98.63%	-99.97%	-80.73%	-100%
S&P	+20.88%	+72.88%	+11.56%	+86%

Evelo Biosciences Company Info

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

News & Analysis

Featured Article

Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.

The potential is significant. Unfortunately, so is the hype.

Maxx Chatsko | Sep 17, 2019

Valuation

Earnings Transcripts

Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript

EVLO earnings call for the period ending June 30, 2022.

Motley Fool Transcribing | Aug 11, 2022

Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript

EVLO earnings call for the period ending December 31, 2021.

Motley Fool Transcribing | Mar 24, 2022

Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript

EVLO earnings call for the period ending September 30, 2021.

Motley Fool Transcribing | Oct 28, 2021

Evelo Biosciences, Inc. (EVLO) Q2 2021 Earnings Call Transcript

EVLO earnings call for the period ending June 30, 2021.

Motley Fool Transcribing | Jul 31, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services